Therapeutic target tailored chemotherapy

PreclinicalSmall molecule

Therapeutic target tailored chemotherapy is one of 3 small molecule programs targeting Rectal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal CarcinomaActive, not recruiting

Rectal CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Rectal Carcinoma

#DrugCompanyPhaseTrials

Lanreotide Acetate

AAlbireo, an Ipsen Company

Adrucil

Therapeutic target tailored chemotherapy

GGrupo Hospital de Madrid

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rectal Carcinoma1 trial

Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients

Completed·GGrupo Hospital de Madrid·N/A·NCT01366118·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Therapeutic target tailored chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Therapeutic target tailored chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Therapeutic target tailored chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Grupo Hospital de Madrid company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGrupo Hospital de Madrid

Therapeutic target tailored chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rectal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News